Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADI-100
- Development stage
- Preclinical
- Lead developer
- Adimune
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
**ADI-100** is Aditxt and its Adimune subsidiary's preclinical, DNA-based antigen-specific immunotherapy derived from the Apoptotic DNA Immunotherapy platform licensed from Loma Linda University. The candidate is intended to induce therapeutically induced immune tolerance by suppressing pathological, antigen- and tissue-specific autoimmune inflammation rather than broadly immunosuppressing the immune system. ADI-100 has been described for autoimmune indications including stiff person syndrome, type 1 diabetes mellitus, psoriasis, and multiple sclerosis; Aditxt has publicly stated plans to advance it toward first-in-human studies, initially emphasizing stiff person syndrome.
02
Targets
GAD2 (Glutamic Acid Decarboxylase 65)
Beyond the preview
Go deeper on ADI-100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADI-100.